^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    ALK1 (Activin A Receptor Like Type 1)

    i
    Other names: ALK1, Activin A Receptor Like Type 1, Serine/Threonine-Protein Kinase Receptor R3, Activin A Receptor Type II-Like 1, TGF-B Superfamily Receptor Type I, Activin Receptor-Like Kinase 1, Activin A Receptor Type IL, ACVRLK1, TSR-I, SKR3, Activin A Receptor, Type II-Like Kinase 1, HHT2
    4d
    Meningioma-like inflammatory myofibroblastic tumor of the lung with TPM3::ALK fusion. (PubMed, Virchows Arch)
    Here, we report a lung IMT in a 45-year-old female demonstrating a unique meningothelial-like pattern, equivocal ALK expression (negative for clone 5A4 and positive for clone ALK1), negative ALK rearrangement by FISH, and the presence of the TPM3::ALK fusion. To our knowledge, this is the first reported case of lung IMT displaying meningothelial-like whorls, with a particular focus on differential diagnosis.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • TPM3 (Tropomyosin 3) • ALK1 (Activin A Receptor Like Type 1)
    |
    ALK positive • ALK rearrangement • ALK fusion • ROS1 rearrangement • ALK negative
    22d
    Subcutaneous Solitary Fibrous Tumor in the Chin of a Young Adult: A Diagnostic Challenge. (PubMed, Am J Case Rep)
    It also underscores the critical role of immunohistochemistry, particularly STAT6 staining, in distinguishing SFT from histologic mimics. Vigilant follow-up remains essential, especially in atypical or CD34-negative cases, given their potential for aggressive behavior.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD34 (CD34 molecule) • ALK1 (Activin A Receptor Like Type 1) • STAT6 (Signal transducer and activator of transcription 6) • CD99 (CD99 Molecule)
    3ms
    Integrating UPLC-Q-TOF-MS and network pharmacology to analyze the components and mechanism of action of Compound Duzhong Zhuangyao Capsules on osteoporosis. (PubMed, Medicine (Baltimore))
    Molecular docking revealed that the core targets were stably bound to the corresponding compounds. This study provides a scientific basis for analyzing the bioactive compounds in Co-DZZY Capsules and their pharmacological mechanisms of action.
    Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • STAT3 (Signal Transducer And Activator Of Transcription 3) • ALK1 (Activin A Receptor Like Type 1) • PPARG (Peroxisome Proliferator Activated Receptor Gamma)
    3ms
    Human immunodeficiency virus negative, immunocompetent primary effusion lymphoma with a complete response on R-miniCHOP. (PubMed, Cytojournal)
    Given his age, the patient started on treatment with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone at reduced doses (R-miniCHOP) and had a complete response. To our knowledge, there are no other reported cases of complete remission following an attenuated R-miniCHOP protocol in this clinical scenario.
    Journal
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • ALK1 (Activin A Receptor Like Type 1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone
    6ms
    Primary Cutaneous Anaplastic Large Cell Lymphoma with Locoregional Lymph Node Involvement: Challenges in Diagnosis and Clinical Management. (PubMed, Am J Dermatopathol)
    Histological and immunophenotypic features were consistent across skin and lymph node biopsies and supported the diagnosis of primary cutaneous origin and were managed with brentuximab vedotin-based chemotherapy, with favorable clinical responses. We emphasize the importance of thorough clinical staging and histopathological correlation to establish the correct diagnosis and the optimal treatment for cases like ours.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8) • ALK1 (Activin A Receptor Like Type 1) • TP63 (Tumor protein 63) • DUSP22 (Dual Specificity Phosphatase 22) • USP22 (Ubiquitin Specific Peptidase 22)
    |
    ALK positive • TNFRSF8 positive • ALK negative
    |
    Adcetris (brentuximab vedotin)
    10ms
    QUILT-3.017: Study of NEO-201 in Solid Tumors Expansion Cohorts (clinicaltrials.gov)
    P1/2, N=121, Recruiting, Precision Biologics, Inc | Trial completion date: Oct 2026 --> Jan 2029 | Trial primary completion date: Oct 2025 --> Jan 2028
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • ALK1 (Activin A Receptor Like Type 1)
    |
    PD-L1 expression • BRAF V600E • TMB-H • MSI-H/dMMR • BRAF V600
    |
    Keytruda (pembrolizumab) • NEO-201
    11ms
    Doxycycline for Hereditary Hemorrhagic Telangiectasia (clinicaltrials.gov)
    P2, N=13, Completed, Unity Health Toronto | Active, not recruiting --> Completed | N=30 --> 13
    Trial completion • Enrollment change
    |
    SMAD4 (SMAD family member 4) • ALK1 (Activin A Receptor Like Type 1)
    1year
    An Unusual Case of Extracavitary/Solid Variant Primary Effusion Lymphoma With Associated Hemophagocytic Lymphohistiocytosis. (PubMed, J Med Cases)
    Solid masses in extracavitary PEL have been shown to involve lymph nodes and/or solid organs such as the gastrointestinal tract, lung, liver, spleen, and skin, with a similar phenotype as classic PEL except that they may express B-cell markers with lower expression of CD45 and/or aberrant coexpression of T-cell antigens. This case illustrates the unusual manifestation of PEL as a mediastinal mass with associated HLH.
    Journal
    |
    CD20 (Membrane Spanning 4-Domains A1) • TNFRSF8 (TNF Receptor Superfamily Member 8) • PAX5 (Paired Box 5) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • ALK1 (Activin A Receptor Like Type 1) • CD5 (CD5 Molecule) • SDC1 (Syndecan 1) • IRF4 (Interferon regulatory factor 4)
    |
    PTPRC expression
    1year
    Prodomain processing controls BMP-10 bioactivity and targeting to fibrillin-1 in latent conformation. (PubMed, FASEB J)
    Binding studies and TEM analyses showed that only the processed BMP-10 CPLX interacts with the N-terminal region of fibrillin-1, causing a conformational change that renders it into a closed ring-shaped conformation. These findings suggest that PD processing induces specific folding events at the PD-GF interface, which is critical for BMP-10 bioactivity and its targeting to the ECM.
    Journal
    |
    ALK1 (Activin A Receptor Like Type 1) • TGFB1 (Transforming Growth Factor Beta 1)
    1year
    An Activin Receptor-Like Kinase 1-governed monocytic lineage shapes an immunosuppressive landscape in breast cancer metastases. (PubMed, J Clin Invest)
    Accordingly, breast cancer patients with a prominent ACVRL1hi TAM signature exhibited a significantly shorter survival. In conclusion, we shed light on an unexpected multimodal regulation of tumorigenic phenotypes by ALK1 and demonstrate its utility as a target for anti-angiogenic immunotherapy.
    Journal • IO biomarker
    |
    ALK1 (Activin A Receptor Like Type 1) • CD14 (CD14 Molecule) • TGFB1 (Transforming Growth Factor Beta 1) • ACVRL1 (Activin A Receptor Like Type 1)
    1year
    Primary gastric T-cell lymphoma presenting with perforation: a case report and review of the literature. (PubMed, J Hematop)
    The diagnosis was peripheral T-cell lymphoma, not otherwise specified, stage IV, consistent with primary gastric lymphoma. To better understand this neoplasm, we performed a comprehensive English language literature review, retrieving clinical, pathologic, immunophenotypic, and molecular data when available, and discussed the most relevant features for diagnosis and classification using the 5th edition of World Health Organization, as well as prognostic features and outcomes of this lymphoma.
    Review • Journal
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • TNFRSF8 (TNF Receptor Superfamily Member 8) • BCL6 (B-cell CLL/lymphoma 6) • CD34 (CD34 molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • NCAM1 (Neural cell adhesion molecule 1) • ALK1 (Activin A Receptor Like Type 1) • CD5 (CD5 Molecule) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • ICOS (Inducible T Cell Costimulator) • MME (Membrane Metalloendopeptidase) • CD7 (CD7 Molecule) • SPN (Sialophorin) • FCER2 (Fc Fragment Of IgE Receptor II) • MPO (Myeloperoxidase)
    1year
    Systemic brain dissemination of glioblastoma requires transdifferentiation into endothelial-like cells via TGF-β-ALK1-Smad1/5 signaling. (PubMed, Neoplasia)
    Consequently, therapeutic targeting of TGF-β-ALK1-Smad1/5 activity impaired endothelialisation-driven glioblastoma progression. This study identifies a previously unknown component of glioblastoma biology and establishes a therapeutic approach to reduce the progression of this disease.
    Journal
    |
    ALK1 (Activin A Receptor Like Type 1) • TGFB1 (Transforming Growth Factor Beta 1) • TGFBR1 (Transforming Growth Factor Beta Receptor 1)